A phase I clinical trial for [¹³¹I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma.

ABSTRACT: Refractory pheochromocytoma and paraganglioma (PPGL) have a poor prognosis and the treatment strategy remains to be established. This multi-institutional phase I study was performed to determine the safety, dose-limiting toxicity (DLT), and efficacy of [¹³¹I]-meta-iodobenzylguanidine (¹³¹I-mIBG) therapy for refractory PPGLs. Twenty patients with refractory PPGL were enrolled in this study. We administered fixed doses of ¹³¹I-mIBG to all patients, delivering a second and third course of ¹³¹I-mIBG to eight and three patients, respectively. During the 20 weeks after ¹³¹I-mIBG injection, the authors surveyed the adverse events in accordance with the Common Terminology Criteria for Adverse Events. All patients experienced adverse events and

SUBMITTER: Wakabayashi H 

PROVIDER: S-EPMC6527850 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature